iTeos Therapeutics, Inc. (NASDAQ:ITOS) Major Shareholder Bioventures 2018 L.P. Mpm Sells 1,149 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Bioventures 2018 L.P. Mpm sold 1,149 shares of the business’s stock in a transaction that occurred on Thursday, October 7th. The stock was sold at an average price of $27.00, for a total transaction of $31,023.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

  • On Monday, October 11th, Bioventures 2018 L.P. Mpm sold 48,812 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.24, for a total transaction of $1,329,638.88.
  • On Monday, October 4th, Bioventures 2018 L.P. Mpm sold 20,711 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.06, for a total transaction of $560,439.66.
  • On Thursday, September 30th, Bioventures 2018 L.P. Mpm sold 2,292 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.00, for a total transaction of $61,884.00.
  • On Monday, September 27th, Bioventures 2018 L.P. Mpm sold 11,625 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.09, for a total transaction of $314,921.25.
  • On Friday, September 24th, Bioventures 2018 L.P. Mpm sold 4,913 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.81, for a total transaction of $136,630.53.
  • On Wednesday, September 22nd, Bioventures 2018 L.P. Mpm sold 14,294 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.54, for a total transaction of $393,656.76.

NASDAQ:ITOS opened at $26.43 on Thursday. The firm’s 50-day moving average price is $26.93 and its 200-day moving average price is $25.34. The company has a market capitalization of $930.60 million, a PE ratio of -12.89 and a beta of 2.21. iTeos Therapeutics, Inc. has a 1-year low of $17.43 and a 1-year high of $47.61.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Thursday, August 12th. The company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.34). As a group, analysts expect that iTeos Therapeutics, Inc. will post 3.22 EPS for the current fiscal year.

A number of research analysts have issued reports on the stock. SVB Leerink reduced their price objective on shares of iTeos Therapeutics from $56.00 to $55.00 and set an “outperform” rating on the stock in a research report on Friday, August 13th. Zacks Investment Research downgraded shares of iTeos Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday.

Large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in shares of iTeos Therapeutics by 97.1% in the 1st quarter. JPMorgan Chase & Co. now owns 9,926 shares of the company’s stock worth $339,000 after buying an additional 4,890 shares during the period. Jane Street Group LLC purchased a new stake in shares of iTeos Therapeutics in the 1st quarter worth about $381,000. New York State Common Retirement Fund grew its position in shares of iTeos Therapeutics by 41.2% in the 1st quarter. New York State Common Retirement Fund now owns 13,700 shares of the company’s stock worth $468,000 after buying an additional 4,000 shares during the period. Chicago Partners Investment Group LLC bought a new position in iTeos Therapeutics in the 2nd quarter worth about $228,000. Finally, BlackRock Inc. boosted its stake in iTeos Therapeutics by 44.0% in the 1st quarter. BlackRock Inc. now owns 1,533,322 shares of the company’s stock worth $52,409,000 after purchasing an additional 468,576 shares in the last quarter. 83.69% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Read More: How to Use the MarketBeat Retirement Calculator

Insider Buying and Selling by Quarter for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.